• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OPNT

    Opiant Pharmaceuticals Inc.

    Subscribe to $OPNT
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

    IPO Year:

    Exchange: NASDAQ

    Website: opiant.com

    Peers

    $SWKH

    Recent Analyst Ratings for Opiant Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    12/9/2021$42.00Outperform
    Oppenheimer
    See more ratings

    Opiant Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Opiant Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Opiant Pharmaceuticals with a rating of Outperform and set a new price target of $42.00

      12/9/21 4:54:31 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Opiant Pharmaceuticals Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/24/23 11:39:07 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

      For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA

      5/22/23 4:58:14 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

      Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

      5/22/23 4:51:13 PM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Opiant Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:27:04 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Collard Craig A returned $1,116,440 worth of shares to the company (55,822 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:25:03 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ruth Matthew R. returned $638,320 worth of shares to the company (31,916 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:22:53 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Daly Richard J returned $156,000 worth of shares to the company (7,800 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:20:53 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Crystal Roger was granted 6,667 shares, returned $1,640,120 worth of shares to the company (82,006 units at $20.00) and returned $102,000 worth of Common Stock par value $0.001 to the company (5,100 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:18:59 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ellison Mark Jason Heath returned $608,620 worth of shares to the company (30,431 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:16:40 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Skolnick Phil returned $470,960 worth of shares to the company (23,548 units at $20.00) and was granted 2,000 shares, closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:13:19 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sinclair Michael returned $1,803,400 worth of shares to the company (90,170 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:10:52 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Macdougall Ann L. returned $563,580 worth of shares to the company (28,179 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:08:29 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Lorianne Masuoka K. returned $80,000 worth of shares to the company (4,000 units at $20.00), closing all direct ownership in the company

      4 - OPIANT PHARMACEUTICALS, INC. (0001385508) (Issuer)

      3/3/23 9:05:53 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care